CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models

ConferenceTazbentetolPositive
AI Analysis

Summary

Spinogenix announced it will present preclinical data at ARVO 2026 showing that Tazbentetol reduces retinal cell loss and preserves visual function in glaucoma and diabetic retinopathy models.

Outcome Details

Preclinical results demonstrating neuroprotective effects showing reduced retinal cell loss and preserved visual function

Importance:4/10
Sentiment:
0.50
preclinicalconference presentationARVO 2026neuroprotectionglaucomadiabetic retinopathyretinal health
Related Companies
$TRAX

Read the original article

Published by PR Newswire Pharma on May 3, 2026 12:43 PM

Read Original